Addressing Low Sexual Desire in Gynecology

James A. Simon, MD, CCD, NCMP, IF, FACOG
Clinical Professor
George Washington University

March 19, 2020 • 4:00-5:00 pm
Brady Auditorium, 310 Cedar St

There is no corporate support for this activity.
Course Director/Host: Lubna Pal, MBBS, FRCOG, MS, FACOG

LEARNING OBJECTIVES:
At the end of this presentation, attendees will be able to:
1. Describe the basics of the classification of female sexual dysfunctions (DSM IV-TR, DSM 5), the incident, prevalence, and overall health burden of Hypoactive Sexual Desire Disorder (HSDD) among women of all ages;
2. Identify and diagnose HSDD in the context of its potential to cause distress, social withdrawal, and relationship conflict; and
3. Review the FDA approved, "off label," non-pharmacological, and investigational pharmacological management options for HSDD/FSD.

DESIGNATION STATEMENT
The Yale School of Medicine designates this live activity for 1 AMA PR-A Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

ACCRREDITATION:
The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE:
ObGyn attending physicians, house staff/fellows, medical students, nurses, PA’s, community Ob/Gyn’s, residents, midwives, nurses and researchers.

NEEDS ASSESSMENT:
Sexual difficulties of all types are under-diagnosed and under-treated. The gynecologist has opportunities and responsibilities to appreciate these disorders and address in evidence-based way.

FACULTY DISCLOSURE:
Course Director: Lubna Pal, MD
Flo Health, Consultant
AMAG Advisory Board, Member
GLG, Consultant
Abbott Advisory Board, Member

DISCLOSURE:
Speaker: James A. Simon, MD
Dr. Simon has grant/research support from: AbbVie, Inc., Bayer Healthcare LLC., Endoceutics, Inc., GTX, Inc., Ipsen, Myovant Sciences, ObsEva SA, TherapeuticsMD, Vieve Medical; is a consultant/advisory boards of AbbVie, Inc., AMAG Pharmaceuticals, Inc., Bayer HealthCare Pharmaceuticals Inc., CEEK Enterprises, LLC., Covance Inc., Dare’ Bioscience, Duchesnay USA, Hologic Inc., KJMDy/NKRe Therapeutics Ltd., Mitsubishi Tanabe Pharma Development America, Inc., Shionogi Inc., Sprott Inc., TherapeuticsMD; serves on the Speaker’s bureaus of AbbVie, Inc., AMAG Pharmaceuticals, Inc., Duchesnay USA, TherapeuticsMD; and is a stockholder (direct purchase) in Sermonix Pharmaceuticals.

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.

YaleCME